Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

@spinnerscircle MNT is rare, especially in a non diabetic population 50-33% were still on the medication at 180 and 360 days. Study is attached. https://t.co/HVwuBbPkOb

“4,066 commercially insured obese members without diabetes that newly initiated #GLP-1 therapy met all study criteria. The mean age was 46 years, and 81% were female. Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year.” https://t.co/CXkYh